THERAPEUTIC POTENTIAL OF CREATINE IN PSYCHIATRY: FROM NEUROBIOLOGY TO CLINICAL APPLICATIONS
Abstract
Mental disorders such as depression, bipolar disorder, schizophrenia, and anxiety are difficult to treat due to their complex neurobiological substrates. Traditional treatments, including pharmacotherapy and psychotherapy, are poor in alleviating symptoms in the majority of patients, where other forms of intervention have been sought. Creatine supplementation, which has been shown to previously improve sports performance, has been looked upon in this context as a form of treatment. Creatine plays a critical role in cellular energy metabolism, particularly in the brain, where it may be useful in the alleviation of energy deficits, oxidative stress, and mitochondrial dysfunction. This review consolidates available information on mechanisms of creatine action, clinical trials, and therapeutic implications in psychiatric disorders and discusses its well-established application in sports with its physiological and molecular effects. Specifically, we address creatine's influence on energy metabolism, neuroprotection, neurotransmitter modulation, and synaptic plasticity. The evidence shows creatine to be a potentially valuable adjunctive treatment, particularly in depression and affective disorders; however, more research is called for to elucidate its whole therapeutic value and develop optimal dosing regimens in heterogeneous patient populations.
References
Persky, A. M., & Rawson, E. S. (2007). Safety of creatine supplementation. Subcellular Biochemistry, 46, 275–289. https://doi.org/10.1007/978-1-4020-6486-9_14
Allen, P. J., D’Anci, K. E., Kanarek, R. B., & Renshaw, P. F. (2010). Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner. Neuropsychopharmacology, 35(2), 534–546. https://doi.org/10.1038/npp.2009.160
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002). Direct antioxidant properties of creatine. Biochemical and Biophysical Research Communications, 290(1), 47– https://doi.org/10.1006/bbrc.2001.6164
Rae, C., Digney, A. L., McEwan, S. R., & Bates, T. C. (2003). Oral creatine monohydrate supplementation improves brain performance: A double-blind, placebo-controlled, cross-over trial. Proceedings of the Royal Society B: Biological Sciences, 270(1529), 2147–2150. https://doi.org/10.1098/rspb.2003.2492
Allen, P. J. (2012). Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? Neuroscience & Biobehavioral Reviews, 36(5), 1442–1462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340488/
Almeida, L. S., Verhoeven, N. M., Roos, B., Valongo, C., Cardoso, M. L., Vilarinho, L., Salomons, G. S., & Jakobs, C. (2004). Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. Molecular genetics and metabolism, 82(3), 214–219. https://doi.org/10.1016/j.ymgme.2004.05.001
Andreazza, A. C., Kauer-Sant’Anna, M., Frey, B. N., Bond, D. J., Kapczinski, F., Young, L. T., & Yatham, L. N. (2008). Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 111(2–3), 135–144. https://doi.org/10.1016/j.jad.2008.04.013
Beal, M. F. (2011). Neuroprotective effects of creatine. Amino Acids, 40(5), 1305–1313. https://doi.org/10.1007/s00726-011-0851-0
Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., ... & Klopstock, T. (2005). Creatine supplementation lowers brain glutamate levels in Huntington’s disease. Journal of Neurology, 252(1), 36–41. https://doi.org/10.1007/s00415-005-0595-4
Bender, A., & Klopstock, T. (2016). Creatine for neuroprotection in neurodegenerative disease: end of story?. Amino acids, 48(8), 1929–1940. https://doi.org/10.1007/s00726-015-2165-0
Coyle, J. T. (2006). Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cellular and Molecular Neurobiology, 26(4–6), 365–384. https://doi.org/10.1007/s10571-006-9062-8
Fukuzako, H., Takeuchi, K., Hokazono, Y., Fukuzako, T., Yamada, K., Hashiguchi, T., Obo, Y., Ueyama, K., Takigawa, M., & Fujimoto, T. (1995). Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry research, 61(4), 193–200. https://doi.org/10.1016/0925-4927(95)02622-5
Hovatta, I., Juhila, J., & Donner, J. (2010). Oxidative stress in anxiety and comorbid disorders. Neuroscience Research, 68(4), 261–275. https://doi.org/10.1016/j.neures.2010.08.007
Iosifescu, D. V., Bolo, N. R., Nierenberg, A. A., Jensen, J. E., Fava, M., & Renshaw, P. F. (2008). Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biological Psychiatry, 63(12), 1127–1134. https://doi.org/10.1016/j.biopsych.2007.11.020
Javitt, D. C. (2007). Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine–glutamate interactions. International Review of Neurobiology, 78, 69–108. https://doi.org/10.1016/S0074-7742(06)78003-5
Kaptsan, A., Odessky, A., Osher, Y., & Levine, J. (2007). Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 68(6), 881–884. https://doi.org/10.4088/jcp.v68n0609
Kato, T., Takahashi, S., Shioiri, T., & Inubushi, T. (1993). Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. Journal of affective disorders, 27(1), 53–59. https://doi.org/10.1016/0165-0327(93)90097-4
Kious, B. M., Kondo, D. G., & Renshaw, P. F. (2019). Creatine for the treatment of depression. Biomolecules, 9(9), 406. https://doi.org/10.3390/biom9090406
Kondo, D. G., Sung, Y. H., Hellem, T. L., Delmastro, K. K., Jeong, E. K., Kim, N., ... & Renshaw, P. F. (2011). Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: A 31-phosphorus magnetic resonance spectroscopy study. Journal of Affective Disorders, 135(1–3), 354–361. https://doi.org/10.1016/j.jad.2011.06.023
Lyoo, I. K., Yoon, S., Kim, T. S., Hwang, J., Kim, J. E., Won, W., ... & Renshaw, P. F. (2012). A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. American Journal of Psychiatry, 169(9), 937–945. https://doi.org/10.1176/appi.ajp.2012.12010009
Burke, D. G., Chilibeck, P. D., Parise, G., Tarnopolsky, M. A., & Candow, D. G. (2003). Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. International journal of sport nutrition and exercise metabolism, 13(3), 294–302. https://doi.org/10.1123/ijsnem.13.3.294
Meyer, L. E., Machado, L. B., Santiago, A. P., da-Silva, W. S., De Felice, F. G., Holub, O., ... & Galina, A. (2006). Mitochondrial creatine kinase activity prevents reactive oxygen species generation: Antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. Journal of Biological Chemistry, 281(49), 37361–37371. https://doi.org/10.1074/jbc.M604123200
Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65(9), 732–741. https://doi.org/10.1016/j.biopsych.2008.11.029
Roitman, S., Green, T., Osher, Y., Karni, N., & Levine, J. (2007). Creatine monohydrate in resistant depression: A preliminary study. Bipolar Disorders, 9(7), 754–758. https://doi.org/10.1111/j.1399-5618.2007.00532.x
Royes, L. F., Fighera, M. R., Furian, A. F., Oliveira, M. S., Myskiw, J.deC., Fiorenza, N. G., Petry, J. C., Coelho, R. C., & Mello, C. F. (2006). Effectiveness of creatine monohydrate on seizures and oxidative damage induced by methylmalonate. Pharmacology, biochemistry, and behavior, 83(1), 136–144. https://doi.org/10.1016/j.pbb.2005.12.017
Sestili, P., Martinelli, C., Colombo, E., Barbieri, E., Potenza, L., Sartini, S., & Fimognari, C. (2011). Creatine as an antioxidant. Amino acids, 40(5), 1385–1396. https://doi.org/10.1007/s00726-011-0875-5
Juneja, K., Bhuchakra, H. P., Sadhukhan, S., Mehta, I., Niharika, A., Thareja, S., Nimmakayala, T., & Sahu, S. (2024). Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions. Cureus, 16(10), e71638. https://doi.org/10.7759/cureus.71638
Toniolo, R. A., Silva, M., Fernandes, F. B. F., Amaral, J. A. M. S., Dias, R. D. S., & Lafer, B. (2018). A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. Journal of neural transmission (Vienna, Austria : 1996), 125(2), 247–257. https://doi.org/10.1007/s00702-017-1817-5
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011). The creatine kinase system and pleiotropic effects of creatine. Amino Acids, 40(5), 1271–1296. https://doi.org/10.1007/s00726-011-0877-3
Views:
306
Downloads:
57
Copyright (c) 2025 Szymon Gnitecki, Jakub Wasiak, Kacper Zielonka, Bartosz Dądela, Marcin Markowski, Natalia Śliwa, Dominika Jakubowska, Eliza Kawalska, Szymon Janczura, Maciej Borowski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
